Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Chemistry Playbook Launched

By Drug Discovery Trends Editor | April 15, 2010

Cambridge Major Laboratories, Inc., Avantium Pharma, Xcelience, LLC, and Beckloff Associates have formed a consortium of expert client-focused companies to launch Chemistry Playbook, a series of proven, modular, expedited CMC solutions designed to accelerate drug development from carbon to commercialization.

Quality can vary across functional business units within larger service providers, but Chemistry Playbook’s consortium model guarantees functional expertise and accountability at every stage. Features and services include Gantt charts and handoffs for individuals or the entire team; and integrated commercial and billing processes to provide natural pull and ease of doing business.

Beckloff Associates (Overland Park, Kan.) offers regulatory oversight; Cambridge Major Laboratories (Germantown, Wisc.) provides API services; Avantium Pharma (Amsterdam, The Netherlands) offers solid state characterization; and Xcelience (Tampa Bay, Fla.) for formulation development expertise.

The consortium launched Chemistry Playbook at a symposium at the headquarters of the Massachusetts Medical Society in Waltham, Mass.

Avantium Pharma’s Vice President Business Development (North America), Andrei Winkler illustrated the advantages of accessing functional expertise across a series of integrated service providers. Beckloff Associates President, Michael Beckloff said, “Innovator companies of all sizes are under pressure to meet critical milestones faster. Execution-based programs can provide significant advantage through time and cost savings.”

This news was featured in Drug Discovery & Development magazine: Vol. 13, No. 3, April 2010, p. 37.

 

 


Filed Under: Drug Discovery

 

Related Articles Read More >

If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
Roche Towers, Basel, Switzerland
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE